6 results match your criteria: "1 Department of Immunology and Institute for Cellular and Molecular Medicine[Affiliation]"
Ann Am Thorac Soc
January 2017
1 Department of Immunology and Institute for Cellular and Molecular Medicine, and.
Identifying mutations that cause cystic fibrosis (CF) is important for making an early, unambiguous diagnosis, which, in turn, is linked to better health and a greater life expectancy. In patients of African descent, a molecular diagnosis is often confounded by the fact that the majority of investigations undertaken to identify causative mutations have been conducted on European populations, and CF-causing mutations tend to be population specific. We undertook a survey of published data with the aim of identifying causative CF mutations in patients of African descent in the Americas.
View Article and Find Full Text PDFPharmacogenomics J
November 2016
Division of Clinical Pharmacology, Toxicology & Innovative Therapeutics, Children's Mercy, and School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.
The relationship between genetic variation in CYP2D6 and variable drug response represents a potentially powerful pharmacogenetic tool. However, little is known regarding this relationship in the genetically diverse South African population. The aim was therefore to evaluate the relationship between predicted and measured CYP2D6 phenotype.
View Article and Find Full Text PDFOncotarget
October 2015
Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy "Iuliu Haţieganu", Cluj Napoca, Romania.
The emergence of genetic engineering at the beginning of the 1970's opened the era of biomedical technologies, which aims to improve human health using genetic manipulation techniques in a clinical context. Gene therapy represents an innovating and appealing strategy for treatment of human diseases, which utilizes vehicles or vectors for delivering therapeutic genes into the patients' body. However, a few past unsuccessful events that negatively marked the beginning of gene therapy resulted in the need for further studies regarding the design and biology of gene therapy vectors, so that this innovating treatment approach can successfully move from bench to bedside.
View Article and Find Full Text PDFJ Virol
July 2015
Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
Unlabelled: Gene-engineered CD34(+) hematopoietic stem and progenitor cells (HSPCs) can be used to generate an HIV-1-resistant immune system. However, a certain threshold of transduced HSPCs might be required for transplantation into mice for creating an HIV-resistant immune system. In this study, we combined CCR5 knockdown by a highly efficient microRNA (miRNA) lentivector with pretransplantation selection of transduced HSPCs to obtain a rather pure population of gene engineered CD34(+) cells.
View Article and Find Full Text PDFJ Biomed Mater Res A
August 2015
Institute for Food, Nutrition and Well-Being and Department of Food Science, University of Pretoria, Private Bag X20, Hatfield, 0028, South Africa.
Kafirin, the sorghum prolamin protein, like its maize homologue zein, can be made into microparticles and films and potentially used as a biomaterial. Zein has good bio- and cyto-compatibility. Kafirin could be advantageous as it is more hydrophobic, more crosslinked, more slowly digested by mammalian proteases than zein and is non-allergenic.
View Article and Find Full Text PDFAppl Transl Genom
December 2013
Department of Immunology and Institute for Cellular and Molecular Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.